Not good!
$Omeros(OMER.US$ • The ARTEMIS-IGAN trial did not reach statistical significance on the primary endpoint of reduction in proteinuria from baseline compared to placebo
• Proteinuria reduction in the placebo group was substantially greater than reported in other IgA nephropathy clinical trials
• Webcast conference call planned for 8:30 a.m. ET today
• Proteinuria reduction in the placebo group was substantially greater than reported in other IgA nephropathy clinical trials
• Webcast conference call planned for 8:30 a.m. ET today
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
